
    
      This is a Phase I, observer-blinded, randomized, controlled multicenter, dose-finding study
      in adult subjects. All vaccines will be administered as a two-dose schedule in (H5N1)
      immunologically-na√Øve adults. Immunogenicity and safety will be evaluated after each
      injection.
    
  